Korean J Gastroenterol.  2013 Aug;62(2):83-84. 10.4166/kjg.2013.62.2.83.

Determining the Dose of Azathioprine Based on the Lower Limit of Leukocyte Count in Patients with Crohn's Disease

• Seo GS

• KMID: 1775743
• DOI: http://doi.org/10.4166/kjg.2013.62.2.83

Abstract

No abstract available.

MeSH Terms

Azathioprine/*therapeutic use
Crohn Disease/*drug therapy
Female
Humans
Immunosuppressive Agents/*therapeutic use
Leukocytes/*cytology
Male
Azathioprine
Immunosuppressive Agents

Reference

References

1. Sandborn W, Sutherland L, Pearson D, May G, Modigliani R, Prantera C. Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. Cochrane Database Syst Rev. 2000; (2):CD000545.

2. Chande N, Tsoulis DJ, MacDonald JK. Azathioprine or 6-mercap-topurine for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2013; 4:CD000545.

3. Lee HJ, Yang SK, Kim KJ, et al. The safety and efficacy of azathioprine and 6-mercaptopurine in the treatment of Korean patients with crohn's disease. Intest Res. 2009; 7:22–31.

4. Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut. 2002; 50:485–489.

5. Kim JH, Cheon JH, Kim WH. The frequency and the course of the adverse effects of azathioprine/6-mercaptopurine treatment in patients with inflammatory bowel disease. Korean J Gastroenterol. 2008; 51:291–297.

6. Connell WR, Kamm MA, Ritchie JK, Lennard-Jones JE. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease:27 years of experience. Gut. 1993; 34:1081–1085.

7. Present DH, Meltzer SJ, Krumholz MP, Wolke A, Korelitz BI. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med. 1989; 111:641–649.

8. Lichtenstein GR. Use of laboratory testing to guide 6-mercapto-purine/azathioprine therapy. Gastroenterology. 2004; 127:1558–1564.

9. Kim WH, Cho JH, Kim TI. Rational dosing of azathioprine and 6-mercaptopurine in inflammatory bowel diseases. Korean J Gastroenterol. 2003; 41:423–437.

10. Hyun KH, Lee SH, Shin JM, et al. Frequency of bone marrow toxicity by using pattern of azathioprine in inflammatory bowel disease patients. Intest Res. 2012; 10:244–250.

11. Kim JH, Cheon JH, Kim TI, Kim WH. A survey of actual clinical practice patterns in the treatment of inflammatory bowel disease in Korea. Intest Res. 2009; 7:79–85.

12. Lim CS, Moon W, Park SJ, et al. How should azathioprine be dosed in Crohn's disease? A novel strategy of maximum dose-ti-tration based on the lower limit of leukocyte count and tolerability. Korean J Gastroenterol. 2013; 62:111–116.